Shimadzu, Indigo BioSystems Partner on Clinical Mass Spec Workflows | GenomeWeb

NEW YORK (GenomeWeb News) – Shimadzu and Indigo BioSystems announced that they have formed a partnership for the development of clinical mass spectrometry workflows.

Under the partnership, the two firms will combine Shimadzu's mass spec instruments with Indigo's Ascent clinical analysis software, a platform for interpreting mass spec data and automatically reviewing that data for problematic results.

The partnership will focus on developing mass spec solutions for applications in clinical research, forensic toxicology, and drug development, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.